Humenza

Humenza is an adjuvanted, inactivated split-virion influenza vaccine developed by Sanofi Pasteur for active immunization against the pandemic H1N1 influenza A virus. The vaccine contains inactivated hemagglutinin (HA) antigen derived from the A/California/07/2009 (H1N1) strain, formulated at 3.8 mcg HA per dose. It is uniquely characterized by the inclusion of AF03, a proprietary squalene-based oil-in-water emulsion adjuvant prepared using a phase inversion temperature (PIT) method. This adjuvant is designed to enhance the immunogenicity of the vaccine, particularly in children and older adults, by promoting higher and more persistent antibody titers compared to unadjuvanted formulations. Humenza was granted marketing authorization in the European Union in 2010 but was subsequently withdrawn by the manufacturer in 2011.

Brand names

Humenza

Other names

pandemic H1N1 influenza vaccine + AF03H1N1v vaccine (AF03-adjuvanted)A/H1N1 influenza vaccine + AF03inactivated influenza vaccine (H1N1) (split virion, adjuvanted)